Clinical Trial Data Transparency (CTDT) which includes “tools and solutions for trial data redaction, anonymization, web portals and data storage and hosting, and trial registration with authorities, among other CTDT requirements.” e-Clinical Platforms that “support the end-to-end needs of clinical trial planning and execution and are composed of integrated solutions used for protocol development, electronic data capture (EDC), clinical trial management systems (CTMSs), randomization and trial supply management systems (RTSMs), electronic trial master files (eTMF), trial analytics and reports, and related capabilities that support clinical trial operations.” Additionally, in their Priority Matrix for Life Science Research and Development 2021, Gartner recognized three areas - e-Clinical Platforms, Clinical Trial Data Transparency (CTDT), and Structured Content Authoring (SBA) and Component Authoring (CBA) – as drivers impacting the digital acceleration of life sciences with the best opportunities to invest in within the next 2 to 5 years for mainstream adoption.Īccording to the Gartner Hype Cycle for Life Science Research and Development report, Anju is cited particularly in the following categories: In the R&D space, Anju was named in the “e-Clinical platforms” category, which Gartner recognized as having a “transformational benefit” in their Priority Matrix for Life Science Research and Development, 2021. Anju Software has also been recognized in the “Key Opinion Leader Management” category in the Gartner Hype Cycle for Life Science Commercial Operations, 2021. Anju’s work providing advanced software technology solutions across the clinical and commercial functions of life sciences was recognized in the “e-Clinical Platforms,” “Clinical Trial Data Transparency,” “Structured Content and Component Authoring” and “Key Opinion Leader Management” sections of the reports. LAUDERDALE, Fla.-( BUSINESS WIRE)-Anju Software has been named by Gartner as a sample vendor in four categories in its 2021 Hype Cycle Life Sciences Research and Development report and Commercial Operations report.
0 kommentar(er)
